License Agreement Sample Contracts

Establishment Labs Holdings Inc. – Development, Supply & License Agreement (June 21st, 2018)

THIS DEVELOPMENT, SUPPLY & LICENSE AGREEMENT ("Agreement"), dated as of the 13th day of December, 2011 (the "Effective Date") is between AorTech International plc with its Affiliates' principal place of business at 19725 South Diamond Lake Road, Rogers Minnesota 55374 ("AorTech") on the one hand, and Establishment Labs, S.A., a Costa Rican corporation with its principal place of business at B15, Zona Franca Coyol, Alajuela, Costa Rica ( "EL"). AorTech and EL are referred together as the "Parties" or separately as a "Party."

Provention Bio, Inc. – License Agreement by and Between Macrogenics, Inc. And Provention Bio, Inc. (June 20th, 2018)

This LICENSE AGREEMENT (this "Agreement") is entered into as of May 7, 2018 (the "Effective Date"), by and between PROVENTION BIO, INC., a Delaware corporation, having its principal place of business at 110 Old Driftway Lane, Lebanon, NJ 08833 ("Provention") and MACROGENICS, INC., a Delaware corporation having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (hereinafter "MacroGenics"). Provention and MacroGenics are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Manufacturing and Distribution License Agreement (June 13th, 2018)

THIS AGREEMENT (Agreement), dated as of June 11, 2018, is entered into by and between Canbiola, Inc., a Florida corporation with a primary place of business at 960 S Broadway Suite 120, Hicksville, NY 11801 (Canbiola) and Hudilab Inc., a Colorado corporation (dba Endless Relief) with a principal place of business at 4833 Front Street Suite B-426 Castle Rock CO 80104.

Provention Bio, Inc. – License Agreement by and Between Macrogenics, Inc. And Provention Bio, Inc. (June 12th, 2018)

This LICENSE AGREEMENT (this "Agreement") is entered into as of May 7, 2018 (the "Effective Date"), by and between PROVENTION BIO, INC., a Delaware corporation, having its principal place of business at 110 Old Driftway Lane, Lebanon, NJ 08833 ("Provention") and MACROGENICS, INC., a Delaware corporation having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (hereinafter "MacroGenics"). Provention and MacroGenics are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

AVROBIO, Inc. – Certain Confidential Portions of This Exhibit Were Omitted and Replaced With [***]. A Complete Version of This Exhibit Has Been Filed Separately With the Secretary of the Securities and Exchange Commission Pursuant to an Application Requesting Confidential Treatment Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended. License Agreement (June 11th, 2018)

A. BioMarin owns and/or controls certain patents and know-how pertaining to a fusion of a portion of the insulin-like growth factor 2 protein (the GILT Tag) with acid alpha-glucosidase and its use in the treatment of Pompe disease.

Immune Therapeutics, Inc. – License Agreement (June 11th, 2018)

This LICENSE AGREEMENT (the "Agreement") is made as of May 1, 2018 (the "Effective Date") by and between Cytocom Inc., a Delaware corporation having its principal place of business at 37 North Orange Ave Suite 607 Orlando Florida 32801 United States ("Cytocom"), and Immune Therapeutics Inc., a company registered under the laws of Florida, and having a registered office at 37 North Orange Ave Suite 607 Orlando Florida 32801 ("Licensee"). This Agreement amends and restates in its entirety the license agreement between the parties, dated September 30, 2014.

Immudyne Inc – License Agreement (June 8th, 2018)

This License Agreement ("Agreement") is made effective as of November_, 2017, ("Effective Date") between One Down, LLC doing business as Scarology (owned by Jeanmarie Connor and Michael Connor, the "Principals") a Florida Limited Liability Company, with an office at 5500 Military Trail #22-186, Jupiter, FL 33458 ("Scarology" or "Licensor"), and Immudyne, PR, LLC, a Puerto Rico Limited Liability Company, with an office at Caribe Plaza Suite 802 Palmeras St #53 San Juan, PR 00901 ("ImmuDyne PR" or "Licensee").

AVROBIO, Inc. – Certain Confidential Portions of This Exhibit Were Omitted and Replaced With [***]. A Complete Version of This Exhibit Has Been Filed Separately With the Secretary of the Securities and Exchange Commission Pursuant to an Application Requesting Confidential Treatment Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended. License Agreement (June 1st, 2018)

A. BioMarin owns and/or controls certain patents and know-how pertaining to a fusion of a portion of the insulin-like growth factor 2 protein (the GILT Tag) with acid alpha-glucosidase and its use in the treatment of Pompe disease.

Neon Therapeutics, Inc. – License Agreement by and Between (May 31st, 2018)

This License Agreement (this Agreement) is entered into as of this 13th day of November, 2015 (the Effective Date), by and between the Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142 (Broad), and Neon Therapeutics, Inc., a Delaware corporation with a principal office at 215 First Street, Cambridge, MA 02142 (Company). Company and Broad are each referred to herein as a Party and collectively as the Parties.

MeiraGTx Holdings plc – Confidential Treatment Requested by MeiraGTx Holdings Plc LICENSE AGREEMENT Between BRANDEIS UNIVERSITY and BRI-Alzan Inc. (May 29th, 2018)

This License Agreement (Agreement), effective as of May 1, 2013 (Effective Date) between Brandeis University, a not-for-profit corporation duly organized and existing under the laws of The Commonwealth of Massachusetts and having its principal place of business at 415 South Street, Waltham, Massachusetts 02454-9110 (Brandeis), and BRI-Alzan Inc., a corporation duly organized and existing under the laws of the State of Delaware and having offices at c/o Fidelity Biosciences Corp., One Main Street, 13th Floor, Cambridge, MA 02142 (hereinafter referred to as Licensee).

AVROBIO, Inc. – Certain Confidential Portions of This Exhibit Were Omitted and Replaced With [***]. A Complete Version of This Exhibit Has Been Filed Separately With the Secretary of the Securities and Exchange Commission Pursuant to an Application Requesting Confidential Treatment Pursuant to Rule 406 Promulgated Under the Securities Act of 1933, as Amended. License Agreement (May 25th, 2018)

A. BioMarin owns and/or controls certain patents and know-how pertaining to a fusion of a portion of the insulin-like growth factor 2 protein (the GILT Tag) with acid alpha-glucosidase and its use in the treatment of Pompe disease.

Smart Energy Solutions Inc – License Agreement (May 25th, 2018)

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel ("Yissum"), of the first part; and CANNA POWDER LTD, of 20 Raul Wallenberg, Tel Aviv, Israel (the "Company"), of the second part; (each of Yissum and the Company, a "Party", and collectively the "Parties")

AVROBIO, Inc. – License Agreement (May 25th, 2018)

This License Agreement (the Agreement) is made and entered into effective as of October 2, 2017 (the Effective Date), by and between

Magenta Therapeutics, Inc. – License Agreement (May 24th, 2018)

THIS LICENSE AGREEMENT (Agreement) is made effective as of the 3rd day of April, 2017 (the Effective Date), by and between Magenta Therapeutics, Inc., a Delaware corporation with its principal place of business located at 50 Hampshire Street, 8th floor, Cambridge, MA 02139 (LICENSEE) and Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (NOVARTIS). LICENSEE and NOVARTIS may, from time-to-time, be individually referred to as a Party and collectively referred to as the Parties.

License Agreement (May 24th, 2018)

This agreement is the commercial equivalent of an agreement for accommodation(s) in a hotel. The whole of the premises remains in Licensor's possession and control. Licensee accepts that this agreement creates no leasehold or other real property interest with respect to the accommodation(s). Licensee is hereby granted a license to use and occupy the Unit(s).

Magenta Therapeutics, Inc. – License Agreement (May 24th, 2018)

This License Agreement (this Agreement) is entered into as of this 2nd day of November, 2016 (the Effective Date), by and between Magenta Therapeutics, Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 245 First St. 4th Floor, Cambridge MA 02142 (Licensee) and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (Harvard).

Zymeworks Inc. – CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. [ *** ] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF a CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION LICENSE AGREEMENT Between ZYMEWORKS INC. And DAIICHI SANKYO COMPANY, LIMITED May 14, 2018 (May 18th, 2018)

THIS LICENSE AGREEMENT (the Agreement), effective as of May 14, 2018 (the Effective Date), by and between DAIICHI SANKYO COMPANY, LIMITED, a corporation organized and existing under the laws of Japan, with its principal business office located at 3-5-1, Nihonbashi honcho, Chuo-ku, Tokyo, 103-8426, Japan (DS) and ZYMEWORKS INC., a corporation organized and existing under the laws of British Columbia, having an address at 540-1385 West 8th Avenue, Vancouver, BC, Canada V6H 3V9 (Zymeworks). Zymeworks and DS are each referred to individually as a Party and together as the Parties.

Amendment No. 5 to the Xbox One Publisher License Agreement (May 17th, 2018)

This Amendment to the Xbox One Publisher License Agreement (this "Amendment") is effective as of September 29, 2017 (the "Amendment Effective Date"), by and between Microsoft Corporation, a Washington corporation ("Microsoft"), and Take-Two Interactive Software, Inc. ("Publisher"), and supplements that certain Xbox One Publisher License Agreement between the parties dated as of October 1, 2013, as amended (the "Xbox One PLA"). This Agreement replaces and supersedes the Amendment No. 5 to the Xbox One Publisher License Agreement (Mixer Incentive) between the parties that was effective September 29, 2017 and executed on December 5, 2017.

Provention Bio, Inc. – License Agreement by and Between Macrogenics, Inc. And Provention Bio, Inc. (May 16th, 2018)

This LICENSE AGREEMENT (this "Agreement") is entered into as of May 7, 2018 (the "Effective Date"), by and between PROVENTION BIO, INC., a Delaware corporation, having its principal place of business at ("Provention") and MACROGENICS, INC., a Delaware corporation having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (hereinafter "MacroGenics"). Provention and MacroGenics are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Antriabio Inc – Amendment No. 1 to the License Agreement (May 15th, 2018)

THIS AMENDMENT NO. 1 (the "Amendment") to the LICENSE AGREEMENT dated as of December 6, 2017 (the "License Agreement"), is entered into on March 30, 2018 (the "Amendment Date") between XOMA (US) LLC, a Delaware limited liability company, having an address of 2200 Powell Street, Suite 310, Emeryville, CA 94608 ("XOMA"), and Rezolute, Inc., a Delaware corporation, having an address of 1450 Infinite Drive, Louisville, CO 80027 ("Rezolute"). Terms used but not otherwise defined herein shall have the meanings ascribed to them in the License Agreement.

License Agreement (May 15th, 2018)

THIS LICENSE AGREEMENT ("Agreement") is made effective April 3, 2018 by and between Rego Payment Architectures, Inc., a Delaware corporation (hereinafter "Licensor" or "Rego"), and Zoom Payment Solutions Inc., a Delaware corporation ("Licensee").

Alcobra Ltd. – License Agreement (May 14th, 2018)

This LICENSE AGREEMENT ("Agreement"') is made as of this 28th day of November, 2012 ("Effective Date"), by and between Protiva Biotherapeutics Inc., a British Columbia corporation ("Protiva"), and Marina Biotech, Inc., a Delaware corporation ("Marina"). Protiva and Marina are each referred to individually as a "Party" and together as the "Parties."

Renren Inc. – Intellectual Property Right License Agreement (May 14th, 2018)

This Intellectual Property Right License Agreement (the "Agreement") entered in Beijing the People's Republic of China (the "PRC," excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan, for the purposes of this Agreement), dated August 18 of 2017 (the "Effective Date"), by and between

Rhythm Pharmaceuticals, Inc. – License Agreement by and Between Takeda Pharmaceutical Company Limited and Rhythm Pharmaceuticals, Inc. (May 14th, 2018)

THIS LICENSE AGREEMENT (this "Agreement") is made effective as of March 30, 2018 (the "Effective Date") by and between Takeda Pharmaceutical Company Limited, a corporation incorporated under the laws of Japan, having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan ("Takeda") and Rhythm Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 500 Boylston Street, 11th Floor, Boston, MA 02116 ("Licensee"). Licensee and Takeda are sometimes referred to herein individually as a "Party" and collectively as the "Parties."

Kiniksa Pharmaceuticals, Ltd. – Confidential Treatment Requested by Kiniksa Pharmaceuticals, Ltd. LICENSE AGREEMENT Between MEDIMMUNE, LIMITED and KINIKSA PHARMACEUTICALS, LTD. (May 14th, 2018)

This License Agreement (the Agreement) is made and entered into effective as of December 21, 2017 (the Effective Date) by and between MedImmune, Limited, a limited liability company duly authorized and existing under the laws of England and Wales (MedImmune) and Kiniksa Pharmaceuticals, Ltd., a Bermuda exempted company (Licensee). MedImmune and Licensee are sometimes referred to herein individually as a Party and collectively as the Parties.

Renren Inc. – Intellectual Property Right License Agreement (May 14th, 2018)

This Intellectual Property Right License Agreement (the "Agreement") entered in Beijing the People's Republic of China (the "PRC", excluding the Hong Kong Special Administrative Region, the Macao Special Administrative Region and Taiwan, for the purposes of this Agreement), dated August 18 of 2017 (the "Effective Date"), by and between

Puma Biotechnology – License Agreement (May 10th, 2018)

Puma Biotechnology, Inc., a corporation organized and existing under the laws of Delaware with offices at 10880 Wilshire Blvd Suite 2150, Los Angeles, CA 90024 ("Puma") and Pint Pharma International SA, a company organised and existing under the laws of Switzerland and having its principal place of business at Route de Chenaux 9, 1091 Bourg-en-Lavaux, Switzerland ("Pint") have entered into this License Agreement as of March 30, 2018 (the "Effective Date").

AMENDMENT NO. 3 to LICENSE AGREEMENT (May 10th, 2018)

THIS AMENDMENT NO. 3 ("Amendment") to that certain License Agreement dated March 29, 2011 (as amended by the amendment No.1 as of June 8, 2011 and the amendment No.2 as of September 16, 2011, collectively, the "Agreement") is made and entered into as of February 13, 2018, by and between Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo"), a company organized under the law of Japan, having a place of business at 6-8 Doshomachi 2-chome, Chuo-ku, Osaka 541-0045 Japan, and Intercept Pharmaceuticals, Inc. ("Intercept"), a company organized under the law of the State of Delaware, having a place of business at 10 Hudson Yards, 37th floors, New York, NY 10001 U.S.A.

License Agreement (May 9th, 2018)

This LICENSE AGREEMENT (the "Agreement") is executed as of March 5, 2018 (the "Effective Date") by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of Delaware and having a place of business at 3911 Sorrento Valley Blvd #110, San Diego, CA 92121 ("Ligand") and Roivant Sciences GmbH, a corporation organized under the laws of Switzerland and having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland ("Licensee"). Ligand and Licensee are each referred to herein by name or, individually, as a "Party" or, collectively, as "Parties."

Prothena Corporation Plc – License Agreement Between Neotope Biosciences Limited and the Regents of the University of California for Case No. Sd2002-035 (May 9th, 2018)

This agreement ("Agreement") is made by and between NEOTOPE BIOSCIENCES LIMITED, a private limited company incorporated under the laws of Ireland with offices at 25- 28 North Wall Quay, Dublin 1, Ireland ("LICENSEE") and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 ("UNIVERSITY"), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 ("UCSD").

Amendment No. 1 to the License Agreement (May 9th, 2018)

THIS AMENDMENT NO. 1 (the "Amendment") to the LICENSE AGREEMENT dated as of December 6, 2017 (the "License Agreement"), is entered into on March 30, 2018 (the "Amendment Date") between XOMA (US) LLC, a Delaware limited liability company, having an address of 2200 Powell Street, Suite 310, Emeryville, CA 94608 ("XOMA"), and Rezolute, Inc., a Delaware corporation, having an address of 1450 Infinite Drive, Louisville, CO 80027 ("Rezolute"). Terms used but not otherwise defined herein shall have the meanings ascribed to them in the License Agreement.

Provention Bio, Inc. – License Agreement (May 9th, 2018)

This License Agreement ("Agreement"), effective as of April 25, 2017 (the "Effective Date"), is made by and between Vactech oy, a corporation organized and existing under the laws of Finland ("Vactech"), and Provention Bio, inc., a corporation organized and existing under the laws of the State of Delaware ("Provention").

Amendment No. 5 to Master Services and License Agreement (May 9th, 2018)

This Amendment No. 5 ("Amendment"), effective as of January 1, 2018 (the "Amendment Effective Date"), is being entered into by and between Marchex Sales LLC, a Delaware limited liability company formerly known as Marchex Sales, Inc., which is a wholly-owned subsidiary of Marchex, Inc. ("Marchex"), and Dex Media, Inc, successor in interest to YellowPages.com LLC formerly doing business as AT&T Interactive or ATTi, ("DexYP"), to amend the Master Services and License Agreement entered between DexYP and Marchex effective as of October 1, 2007 (as amended by all prior amendments, Change Rule Sheets, and Project Addenda, as amended, thereto, and including all attachments, collectively the "Agreement"). DexYP and Marchex may hereinafter be referred to individually as "Party" and collectively as "Parties." Capitalized terms used herein but not defined shall have the respective meanings ascribed to them in the Agreement.

Prothena Corporation Plc – License Agreement Amendment Number One (May 9th, 2018)

This License Agreement Amendment Number One (the "Amendment") is made as of January 15, 2014 (the "Amendment Effective Date") by and between Neotope Biosciences Limited, a private limited company incorporated under the laws of Ireland with offices at 25-28 North Wall Quay, Dublin 1, Ireland ("LICENSEE") and The Regents of the University of California, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 ("UNIVERSITY"), represented by its San Diego campus having an address at University of California, San Diego, Technology Transfer Office, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 ("UCSD").

Stevens Holding Company, Inc. – Form of Intellectual Property Cross-License Agreement (May 8th, 2018)

THIS INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this Agreement) is made as of [*] (the Effective Date) by and between Fortive Corporation, a Delaware corporation (Fortive), Altra Industrial Motion Corp, a Delaware corporation (Altra), on behalf of itself and its Subsidiaries, including Stevens Holding Company, Inc., a Delaware corporation (Newco) and the Direct Sales Purchasers (as defined below). Altra and Fortive are collectively referred to herein as the Parties and each individually referred to herein as a Party. Capitalized terms used herein without being defined in this Agreement shall have the respective meanings given such terms in the Separation and Distribution Agreement, dated as of March 7, 2018 (as amended, modified or supplemented from time to time in accordance with its terms, the Distribution Agreement), by and between Fortive, Newco and Altra.